MD, DM (Gastro), Department of Gastroenterology, Sir Ganga Ram Hospital, Delhi, India; Corresponding Author.
J Assoc Physicians India. 2023 Aug;71(8):11-12. doi: 10.59556/japi.71.0322.
In the last 3 decades, omeprazole has proved its mettle in managing acid peptic diseases (APDs). It has established itself as the first line of therapy for duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), ulcers due to nonsteroidal anti-inflammatory drugs (NSAID), and Zollinger-Ellison syndrome (ZES).
The purpose of this literature review is to assess the effectiveness of omeprazole as compared to the other proton pump inhibitors (PPIs) currently in use and its safety and efficacy in special populations, including the pediatric and geriatric populations.
Omeprazole was found to be the most effective PPI in the management of APDs due to its rapid action, good antioxidant effects, and effectiveness against nocturnal acid breakthroughs. Its safety and tolerance have been proved in various randomized controlled trials.
Omeprazole is the prototypical drug in the management of APDs and has withstood the test of time. After 3 decades, omeprazole remains the drug of choice in managing APD.
在过去的 30 年中，奥美拉唑已经证明了其在治疗酸相关疾病方面的实力。它已成为十二指肠和胃溃疡、胃食管反流病（GERD）、非甾体抗炎药（NSAID）相关溃疡和卓-艾综合征（ZES）的一线治疗药物。
本文献综述旨在评估奥美拉唑与目前使用的其他质子泵抑制剂（PPIs）相比的有效性，以及其在特殊人群（包括儿科和老年人群）中的安全性和疗效。
由于奥美拉唑具有快速作用、良好的抗氧化作用和对夜间胃酸突破的有效性，它被认为是治疗酸相关疾病的最有效 PPI。在各种随机对照试验中已经证明了其安全性和耐受性。
奥美拉唑是酸相关疾病治疗的典型药物，经受住了时间的考验。30 年后，奥美拉唑仍然是治疗酸相关疾病的首选药物。
